Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Microbiota and Cancer 3.0
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Microbiota and Cancer 3.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 28330

Special Issue Editors

Dr. Riccardo Masetti

E-Mail Website
Guest Editor
Pediatric Hematology-Oncology Unit, Department of Medical and Surgical Sciences DIMEC, University of Bologna, Bologna, Italy
Interests: acute myeloid leukemia in children; pediatric myelodysplastic syndrome; hematopoietic stem cell transplantation in children; next-generation sequencing; characterization and modulation of gut microbiota during hematopoietic stem cell transplantation
Special Issues, Collections and Topics in MDPI journals
Dr. Silvia Turroni

E-Mail Website
Guest Editor
Department of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro, 6-40126 Bologna, Italy
Interests: human microbiome; gut microbiome; microbial ecology; host–microbiome interactions; probiotics; next-generation sequencing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the continuation of our previous Special Issues, titled "Microbiota and Cancer" and "Microbiota and Cancer 2.0".

The human body is colonized by thousands of different microbial species that have a key role in our survival. In the last 15 years, our knowledge of human microbiomes has increased exponentially. Thanks to next-generation DNA sequencing, metabolomics, and genobiotic models, we could dissect compositional and functional microbiome structures, and infer the mechanisms underlying the role of the microbiome in human biology and pathology. Mounting evidence has suggested a critical role of the microbiome in the maturation and continued education of the host immune response in susceptibility to cancer and in response to cancer treatment. The impact of the gut microbiota on anticancer immune responses has represented an intriguing and evolving scenario in the recent literature. Novel metacommunity approaches have provided an integrative and extensive vision of the tight link between microbiomes and cancer, and have offered new exciting insights into possible therapeutic implications.

This Special Issue titled “Microbiota and Cancer 3.0” will focus on the role of the human microbiome in the pathogenesis of cancer, in response to immunotherapy, in hematopoietic stem cell transplantation, and in possible microbiota-based therapeutic or pre-emptive strategies to manage treatment-related complications.

Authors are invited to submit original research and review papers which address the abovementioned topics to this Special Issue.

Dr. Riccardo Masetti
Dr. Silvia Turroni
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gut microbiota
  • cancer
  • hematopoietic stem cell transplantation
  • human microbiome
  • immune system
  • colon cancer
  • carcinogenesis
  • nutrition
  • short-chain fatty acids
  • metagenomic
  • dysbiosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (10 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

11 pages, 2137 KiB  
Article
Intestinal Microbiota Increases Cell Proliferation of Colonic Mucosa in Human-Flora-Associated (HFA) Mice
by Giovanni Brandi, Carlo Calabrese, Simona Tavolari, Chantal Bridonneau, Pierre Raibaud, Giuseppina Liguori, Muriel Thomas, Monica Di Battista, Valerie Gaboriau-Routhiau and Philippe Langella
Int. J. Mol. Sci. 2024, 25(11), 6182; https://doi.org/10.3390/ijms25116182 - 4 Jun 2024
Viewed by 886
Abstract
Intestinal epithelium renewal strictly depends on fine regulation between cell proliferation, differentiation, and apoptosis. While murine intestinal microbiota has been shown to modify some epithelial cell kinetics parameters, less is known about the role of the human intestinal microbiota. Here, we investigated the [...] Read more.
Intestinal epithelium renewal strictly depends on fine regulation between cell proliferation, differentiation, and apoptosis. While murine intestinal microbiota has been shown to modify some epithelial cell kinetics parameters, less is known about the role of the human intestinal microbiota. Here, we investigated the rate of intestinal cell proliferation in C3H/HeN germ-free mice associated with human flora (HFA, n = 8), and in germ-free (n = 15) and holoxenic mice (n = 16). One hour before sacrifice, all mice were intraperitoneally inoculated with 5-bromodeoxyuridine (BrdU), and the number of BrdU-positive cells/total cells (labelling index, LI), both in the jejunum and the colon, was evaluated by immunohistochemistry. Samples were also observed by scanning electron microscopy (SEM). Moreover, the microbiota composition in the large bowel of the HFA mice was compared to that of of human donor’s fecal sample. No differences in LI were found in the small bowels of the HFA, holoxenic, and germ-free mice. Conversely, the LI in the large bowel of the HFA mice was significantly higher than that in the germ-free and holoxenic counterparts (p = 0.017 and p = 0.048, respectively). In the holoxenic and HFA mice, the SEM analysis disclosed different types of bacteria in close contact with the intestinal epithelium. Finally, the colonic microbiota composition of the HFA mice widely overlapped with that of the human donor in terms of dominant populations, although Bifidobacteria and Lactobacilli disappeared. Despite the small sample size analyzed in this study, these preliminary findings suggest that human intestinal microbiota may promote a high proliferation rate of colonic mucosa. In light of the well-known role of uncontrolled proliferation in colorectal carcinogenesis, these results may deserve further investigation in a larger population study. Full article
(This article belongs to the Special Issue Microbiota and Cancer 3.0)
►▼ Show Figures

Figure 1

16 pages, 3842 KiB  
Article
Performance of a Shotgun Prediction Model for Colorectal Cancer When Using 16S rRNA Sequencing Data
by Elies Ramon, Mireia Obón-Santacana, Olfat Khannous-Lleiffe, Ester Saus, Toni Gabaldón, Elisabet Guinó, David Bars-Cortina, Gemma Ibáñez-Sanz, Lorena Rodríguez-Alonso, Alfredo Mata, Ana García-Rodríguez and Victor Moreno
Int. J. Mol. Sci. 2024, 25(2), 1181; https://doi.org/10.3390/ijms25021181 - 18 Jan 2024
Viewed by 1807
Abstract
Colorectal cancer (CRC), the third most common cancer globally, has shown links to disturbed gut microbiota. While significant efforts have been made to establish a microbial signature indicative of CRC using shotgun metagenomic sequencing, the challenge lies in validating this signature with 16S [...] Read more.
Colorectal cancer (CRC), the third most common cancer globally, has shown links to disturbed gut microbiota. While significant efforts have been made to establish a microbial signature indicative of CRC using shotgun metagenomic sequencing, the challenge lies in validating this signature with 16S ribosomal RNA (16S) gene sequencing. The primary obstacle is reconciling the differing outputs of these two methodologies, which often lead to divergent statistical models and conclusions. In this study, we introduce an algorithm designed to bridge this gap by mapping shotgun-derived taxa to their 16S counterparts. This mapping enables us to assess the predictive performance of a shotgun-based microbiome signature using 16S data. Our results demonstrate a reduction in performance when applying the 16S-mapped taxa in the shotgun prediction model, though it retains statistical significance. This suggests that while an exact match between shotgun and 16S data may not yet be feasible, our approach provides a viable method for comparative analysis and validation in the context of CRC-associated microbiome research. Full article
(This article belongs to the Special Issue Microbiota and Cancer 3.0)
►▼ Show Figures

Figure 1

19 pages, 1640 KiB  
Article
Gut Microbiota, Metabolome, and Body Composition Signatures of Response to Therapy in Patients with Advanced Melanoma
by Giulia Vandoni, Federica D'Amico, Marco Fabbrini, Luigi Mariani, Sabina Sieri, Amanda Casirati, Lorenza Di Guardo, Michele Del Vecchio, Andrea Anichini, Roberta Mortarini, Francesco Sgambelluri, Giuseppe Celano, Nadia Serale, Maria De Angelis, Patrizia Brigidi, Cecilia Gavazzi and Silvia Turroni
Int. J. Mol. Sci. 2023, 24(14), 11611; https://doi.org/10.3390/ijms241411611 - 18 Jul 2023
Cited by 7 | Viewed by 2225
Abstract
Despite the recent breakthroughs in targeted and immunotherapy for melanoma, the overall survival rate remains low. In recent years, considerable attention has been paid to the gut microbiota and other modifiable patient factors (e.g., diet and body composition), though their role in influencing [...] Read more.
Despite the recent breakthroughs in targeted and immunotherapy for melanoma, the overall survival rate remains low. In recent years, considerable attention has been paid to the gut microbiota and other modifiable patient factors (e.g., diet and body composition), though their role in influencing therapeutic responses has yet to be defined. Here, we characterized a cohort of 31 patients with unresectable IIIC-IV-stage cutaneous melanoma prior to initiation of targeted or first-line immunotherapy via the following methods: (i) fecal microbiome and metabolome via 16S rRNA amplicon sequencing and gas chromatography/mass spectrometry, respectively, and (ii) anthropometry, body composition, nutritional status, physical activity, biochemical parameters, and immunoprofiling. According to our data, patients subsequently classified as responders were obese (i.e., with high body mass index and high levels of total, visceral, subcutaneous, and intramuscular adipose tissue), non-sarcopenic, and enriched in certain fecal taxa (e.g., Phascolarctobacterium) and metabolites (e.g., anethole), which were potentially endowed with immunostimulatory and oncoprotective activities. On the other hand, non-response was associated with increased proportions of Streptococcus, Actinomyces, Veillonella, Dorea, Fusobacterium, higher neutrophil levels (and a higher neutrophil-to-lymphocyte ratio), and higher fecal levels of butyric acid and its esters, which also correlated with decreased survival. This exploratory study provides an integrated list of potential early prognostic biomarkers that could improve the clinical management of patients with advanced melanoma, in particular by guiding the design of adjuvant therapeutic strategies to improve treatment response and support long-term health improvement. Full article
(This article belongs to the Special Issue Microbiota and Cancer 3.0)
►▼ Show Figures

Figure 1

13 pages, 2059 KiB  
Article
Vaginal and Cervical Microbiota Composition in Patients with Endometrial Cancer
by Bartłomiej Barczyński, Karolina Frąszczak, Ewelina Grywalska, Jan Kotarski and Izabela Korona-Głowniak
Int. J. Mol. Sci. 2023, 24(9), 8266; https://doi.org/10.3390/ijms24098266 - 5 May 2023
Cited by 10 | Viewed by 2881
Abstract
According to recent data, changes in the vaginal microbiota could affect the risk of gynaecological cancers. Women suffering from endometrial cancer present significant changes in cervicovaginal microbiota composition. The objective of our study was to characterize the cervicovaginal microbiota of women undergoing hysterectomy [...] Read more.
According to recent data, changes in the vaginal microbiota could affect the risk of gynaecological cancers. Women suffering from endometrial cancer present significant changes in cervicovaginal microbiota composition. The objective of our study was to characterize the cervicovaginal microbiota of women undergoing hysterectomy due to benign disease, atypical hyperplasia, and endometrial cancer; The study included 96 patients, who undergone surgical treatment due to benign uterine disease, precancerous endometrial lesion, and endometrial cancer. Quantitative and qualitative real-time PCR analysis of DNA isolated from vaginal fornix and endocervical canal samples was performed to detect the 19 most commonly identified microorganisms, including different Lactobacillus spp., Atopobium, Bifidobacterium, Chlamydia, and Gardnerella; At least one of the tested microorganisms was identified in 88.5% of vaginal and 83.3% of cervical samples. Lactobacillus iners was significantly more frequent in patients with benign condition, whereas Dialister pneumosintes and Mobiluncus curtisii was more frequent in cancer patients; Mobiluncus curtisi and Dialister pneumosintes, which were identified as significantly more common in endometrial cancer vaginal samples, may be considered as potential endometrial cancer co-factors which promote/stimulate carcinogenesis. However, the exact mechanism of such activity remains unexplained and requires further investigations. Full article
(This article belongs to the Special Issue Microbiota and Cancer 3.0)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

22 pages, 1723 KiB  
Review
Modulation of Gut Microbial Biomarkers and Metabolites in Cancer Management by Tea Compounds
by Hoi Kit Matthew Leung, Emily Kwun Kwan Lo, Fangfei Zhang, Felicianna, Marsena Jasiel Ismaiah, Congjia Chen and Hani El-Nezami
Int. J. Mol. Sci. 2024, 25(12), 6348; https://doi.org/10.3390/ijms25126348 - 8 Jun 2024
Viewed by 1826
Abstract
Cancers are causing millions of deaths and leaving a huge clinical and economic burden. High costs of cancer drugs are limiting their access to the growing number of cancer cases. The development of more affordable alternative therapy could reach more patients. As gut [...] Read more.
Cancers are causing millions of deaths and leaving a huge clinical and economic burden. High costs of cancer drugs are limiting their access to the growing number of cancer cases. The development of more affordable alternative therapy could reach more patients. As gut microbiota plays a significant role in the development and treatment of cancer, microbiome-targeted therapy has gained more attention in recent years. Dietary and natural compounds can modulate gut microbiota composition while providing broader and more accessible access to medicine. Tea compounds have been shown to have anti-cancer properties as well as modulate the gut microbiota and their related metabolites. However, there is no comprehensive review that focuses on the gut modulatory effects of tea compounds and their impact on reshaping the metabolic profiles, particularly in cancer models. In this review, the effects of different tea compounds on gut microbiota in cancer settings are discussed. Furthermore, the relationship between these modulated bacteria and their related metabolites, along with the mechanisms of how these changes led to cancer intervention are summarized. Full article
(This article belongs to the Special Issue Microbiota and Cancer 3.0)
►▼ Show Figures

Figure 1

17 pages, 823 KiB  
Review
Microbiota–Gastric Cancer Interactions and the Potential Influence of Nutritional Therapies
by Pauline Raoul, Valeria Maccauro, Marco Cintoni, Emidio Scarpellini, Gianluca Ianiro, Antonio Gasbarrini, Maria Cristina Mele and Emanuele Rinninella
Int. J. Mol. Sci. 2024, 25(3), 1679; https://doi.org/10.3390/ijms25031679 - 30 Jan 2024
Cited by 3 | Viewed by 2394
Abstract
Gastric cancer (GC) is one of the most common causes of cancer deaths, and GC treatments represent a large area of research. Although initially regarded as a sterile organ and unsuitable for microbial communities, the discovery of Helicobacter pylori made us realize that some [...] Read more.
Gastric cancer (GC) is one of the most common causes of cancer deaths, and GC treatments represent a large area of research. Although initially regarded as a sterile organ and unsuitable for microbial communities, the discovery of Helicobacter pylori made us realize that some microbes can colonize the stomach. In recent years, growing interest in gastric bacteria has expanded to the gut microbiota and, more recently, to the oral microbiota. Indeed, the oral–gastric–gut microbiota axis may play a crucial role in maintaining homeostasis, while changes in microbiota composition in GC patients can influence clinical outcomes. On the one hand, the microbiota and its metabolites may significantly influence the progression of GC, while anti-GC treatments such as gastrectomy and chemotherapy may significantly impact the oral–gastric–gut microbiota axis of GC patients. In this context, the role of nutritional therapies, including diet, prebiotics, and probiotics, in treating GC should not be underestimated. Wit this review, we aim to highlight the main role of the gastric, oral, and gut microbiota in GC onset and progression, representing potential future biomarkers for early GC detection and a target for efficient nutritional therapies during the course of GC. Full article
(This article belongs to the Special Issue Microbiota and Cancer 3.0)
►▼ Show Figures

Figure 1

20 pages, 1555 KiB  
Review
Exploring the Role of the Gut and Intratumoral Microbiomes in Tumor Progression and Metastasis
by Aneta Sevcikova, Beata Mladosievicova, Michal Mego and Sona Ciernikova
Int. J. Mol. Sci. 2023, 24(24), 17199; https://doi.org/10.3390/ijms242417199 - 6 Dec 2023
Cited by 8 | Viewed by 4835
Abstract
Cancer cell dissemination involves invasion, migration, resistance to stressors in the circulation, extravasation, colonization, and other functions responsible for macroscopic metastases. By enhancing invasiveness, motility, and intravasation, the epithelial-to-mesenchymal transition (EMT) process promotes the generation of circulating tumor cells and their collective migration. [...] Read more.
Cancer cell dissemination involves invasion, migration, resistance to stressors in the circulation, extravasation, colonization, and other functions responsible for macroscopic metastases. By enhancing invasiveness, motility, and intravasation, the epithelial-to-mesenchymal transition (EMT) process promotes the generation of circulating tumor cells and their collective migration. Preclinical and clinical studies have documented intensive crosstalk between the gut microbiome, host organism, and immune system. According to the findings, polymorphic microbes might play diverse roles in tumorigenesis, cancer progression, and therapy response. Microbial imbalances and changes in the levels of bacterial metabolites and toxins promote cancer progression via EMT and angiogenesis. In contrast, a favorable microbial composition, together with microbiota-derived metabolites, such as short-chain fatty acids (SCFAs), can attenuate the processes of tumor initiation, disease progression, and the formation of distant metastases. In this review, we highlight the role of the intratumoral and gut microbiomes in cancer cell invasion, migration, and metastatic ability and outline the potential options for microbiota modulation. As shown in murine models, probiotics inhibited tumor development, reduced tumor volume, and suppressed angiogenesis and metastasis. Moreover, modulation of an unfavorable microbiome might improve efficacy and reduce treatment-related toxicities, bringing clinical benefit to patients with metastatic cancer. Full article
(This article belongs to the Special Issue Microbiota and Cancer 3.0)
►▼ Show Figures

Graphical abstract

29 pages, 2409 KiB  
Review
How Can the Microbiome Induce Carcinogenesis and Modulate Drug Resistance in Cancer Therapy?
by Inês Mendes and Nuno Vale
Int. J. Mol. Sci. 2023, 24(14), 11855; https://doi.org/10.3390/ijms241411855 - 24 Jul 2023
Cited by 6 | Viewed by 3061
Abstract
Over the years, cancer has been affecting the lives of many people globally and it has become one of the most studied diseases. Despite the efforts to understand the cell mechanisms behind this complex disease, not every patient seems to respond to targeted [...] Read more.
Over the years, cancer has been affecting the lives of many people globally and it has become one of the most studied diseases. Despite the efforts to understand the cell mechanisms behind this complex disease, not every patient seems to respond to targeted therapies or immunotherapies. Drug resistance in cancer is one of the limiting factors contributing to unsuccessful therapies; therefore, understanding how cancer cells acquire this resistance is essential to help cure individuals affected by cancer. Recently, the altered microbiome was observed to be an important hallmark of cancer and therefore it represents a promising topic of cancer research. Our review aims to provide a global perspective of some cancer hallmarks, for instance how genetic and epigenetic modifications may be caused by an altered human microbiome. We also provide information on how an altered human microbiome can lead to cancer development as well as how the microbiome can influence drug resistance and ultimately targeted therapies. This may be useful to develop alternatives for cancer treatment, i.e., future personalized medicine that can help in cases where traditional cancer treatment is unsuccessful. Full article
(This article belongs to the Special Issue Microbiota and Cancer 3.0)
►▼ Show Figures

Figure 1

12 pages, 658 KiB  
Review
Biotherapy Using Probiotics as Therapeutic Agents to Restore the Gut Microbiota to Relieve Gastrointestinal Tract Inflammation, IBD, IBS and Prevent Induction of Cancer
by Divakar Dahiya and Poonam Singh Nigam
Int. J. Mol. Sci. 2023, 24(6), 5748; https://doi.org/10.3390/ijms24065748 - 17 Mar 2023
Cited by 27 | Viewed by 4750
Abstract
The gut microbiota is composed of several microbial strains with diverse and variable compositions in both healthy and sick people. An undisturbed gut microbiota needs to be sustained in order to perform all physiological, metabolic, and immune functions in a normal way to [...] Read more.
The gut microbiota is composed of several microbial strains with diverse and variable compositions in both healthy and sick people. An undisturbed gut microbiota needs to be sustained in order to perform all physiological, metabolic, and immune functions in a normal way to prevent the development of diseases. This article has reviewed the published information on the issue of disruption of the balance of the gut microbiota. This disruption could be for many reasons, such as microbial infection in the gastrointestinal tract, food poisoning, diarrhoea, chemotherapy, malnutrition, lifestyle, and ageing. If this disruption is not restored to normal, it might cause dysbiosis. Eventually, a gut microbiota interrupted by dysbiosis might initiate several health issues, such as inflammation of the gastrointestinal tract, the induction of cancer, and the progression of a variety of diseases such as irritable bowel syndrome and inflammatory bowel disease. This review concluded that biotherapy is a natural way of using probiotic products, whether in form of food, beverages, or supplements, to restore the gut microbiota disrupted by dysbiosis. Metabolites secreted by the ingested probiotics help to relieve gastrointestinal tract inflammation and can avoid the induction of cancer. Full article
(This article belongs to the Special Issue Microbiota and Cancer 3.0)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

11 pages, 1876 KiB  
Hypothesis
Ovarian Microbiota, Ovarian Cancer and the Underestimated Role of HPV
by Massimiliano Cazzaniga, Marco Cardinali, Francesco Di Pierro and Alexander Bertuccioli
Int. J. Mol. Sci. 2022, 23(24), 16019; https://doi.org/10.3390/ijms232416019 - 16 Dec 2022
Cited by 4 | Viewed by 2624
Abstract
In recent years, many studies have highlighted the possible close correlation between human diseases and definite patterns of microbial organisms colonizing various organs. Even at sites traditionally considered sterile, such as the upper female reproductive tract (FRT), it is now well-recognized as hosting [...] Read more.
In recent years, many studies have highlighted the possible close correlation between human diseases and definite patterns of microbial organisms colonizing various organs. Even at sites traditionally considered sterile, such as the upper female reproductive tract (FRT), it is now well-recognized as hosting a low biomass of different bacterial phyla. Additionally, the data from recent studies highlight a possible link between lower and upper FRT dysbiosis with a potential predisposition to cervical and ovarian cancer. Acinetobacter, chlamydia, increased mycoplasma, and lactobacillary scarcity in the upper FRT have all been linked to a predisposition to ovarian cancer. Additionally, a high-diversity vaginal community state type (CST) is linked to the presence and persistence of high-risk human papillomavirus (HPV), resulting in decreased cellular p53 activity and a reduction in the immune activity of T lymphocytes, resulting in cervical and ovarian cancer predisposition. While these findings are still far from being clarified in all aspects, in patients with multiple risk factors for ovarian cancer, a Lactobacillus crispatus treatment with a product with a proven ability to restore a favorable CST should be considered as an add-on therapy. Full article
(This article belongs to the Special Issue Microbiota and Cancer 3.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-10
Back to TopTop